GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (FRA:RAH) » Definitions » Institutional Ownership

Societal CDMO (FRA:RAH) Institutional Ownership : 11.35% (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Societal CDMO Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Societal CDMO's institutional ownership is 11.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Societal CDMO's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Societal CDMO's Float Percentage Of Total Shares Outstanding is 81.91%.


Societal CDMO Institutional Ownership Historical Data

The historical data trend for Societal CDMO's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Institutional Ownership Chart

Societal CDMO Historical Data

The historical data trend for Societal CDMO can be seen below:

2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31
Institutional Ownership 15.12 13.60 14.73 14.73 12.67 13.14 11.20 11.20 11.35 11.35

Societal CDMO Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Societal CDMO (FRA:RAH) Business Description

Traded in Other Exchanges
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

Societal CDMO (FRA:RAH) Headlines

No Headlines